SPOTLIGHT -
Dr. Gafita on Prognostic Models for Treatment With 177Lu-PSMA-617 in mCRPC
Andrei Gafita, MD, discusses key takeaways from a retrospective analysis evaluating lutetium-177 PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Read More
Dr. Gafita on the Opportunity for 177Lu-PSMA-617 in mCRPC
Andrei Gafita, MD, discusses available therapies for men with advanced castration-resistant prostate cancer.
Dr. Gafita on the Rationale to Evaluate 177Lu-PSMA-617 in mCRPC
Andrei Gafita, MD, discusses the rationale to evaluate lutetium-177 PSMA-617 in metastatic castration-resistant prostate cancer.
Dr. Gafita on Sequencing 177Lu-PSMA-617 in mCRPC
Andrei Gafita, MD, discusses sequencing lutetium-177 PSMA-617 in metastatic castration-resistant prostate cancer.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
